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Small angle X-ray scattering
Solid state NMR
Molecular dynamicsDrug–membrane interactions of the candesartan cilexetil (TCV-116) have been studied on molecular basis by
applying various complementary biophysical techniques namely differential scanning calorimetry (DSC),
Raman spectroscopy, small and wide angle X-ray scattering (SAXS and WAXS), solution 1H and 13C nuclear
magnetic resonance (NMR) and solid state 13C and 31P (NMR) spectroscopies. In addition, 31P cross polariza-
tion (CP) NMR broadline ﬁtting methodology in combination with ab initio computations has been applied.
Finally molecular dynamics (MD) was applied to ﬁnd the low energy conformation and position of
candesartan cilexetil in the bilayers. Thus, the experimental results complemented with in silico MD results
provided information on the localization, orientation, and dynamic properties of TCV-116 in the lipidic envi-
ronment. The effects of this prodrug have been compared with other AT1 receptor antagonists hitherto stud-
ied. The prodrug TCV-116 as other sartans has been found to be accommodated in the polar/apolar interface
of the bilayer. In particular, it anchors in the mesophase region of the lipid bilayers with the tetrazole group
oriented toward the polar headgroup spanning from water interface toward the mesophase and upper seg-
ment of the hydrophobic region. In spite of their localization identity, their thermal and dynamic effects
are distinct pointing out that each sartan has its own ﬁngerprint of action in the membrane bilayer, which
is determined by the parameters derived from the above mentioned biophysical techniques.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Angiotensin II (AngII) receptor blockers (ARBs) are amphiphilic
molecules that exert their biological activity by preventing the vaso-
constrictive hormone AngII to act on the AT1 receptor [1,2]. The mo-
lecular basis of their antihypertensive action has been interpreted
by a two-step model. In the ﬁrst step they are incorporated into the
bilayers through the lipid–water interface and secondly laterally dif-
fuse to reach the active site of the AT1 receptor in order to exert
their biological activity [3–5].+39 40 375 8029.
+30 2107274761.
M. Rappolt),
rights reserved.The prodrug 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl, 2-ethoxy-1-
[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1H-benzimidazole-
7-carboxylate denoted as candesartan cilexetil (TCV-116) (see Fig. 1a)
is esteriﬁed at the carboxyl group by the cyclohexylocarbonyloxyethyl
segment of the active compound candesartan (CV-11974) (see Fig. 1b),
that belong to sartans antihypertensive drugs [6,7].
The cellular membranes are complex entities consisting of various
kinds of proteins and lipids as well as cholesterol. Phosphatidylcholines
(PCs) are the most abundant lipid species in the plasma membranes of
the vascular smooth muscle cells [8] and sarcolemma cardiac mem-
branes [9]. The most frequently found among them are PCs with oleic
and linoleic chains, and further dipalmitoylphosphatidylcholine
(DPPC). Hydrated DPPC lipids are used because they spontaneously
form multilamellar bilayers whose mesomorphic changes occur in a
convenient temperature range between 25 and 50 °C. Their dynamic
Fig. 1. The chemical structures of (a) candesartan cilexetil, (b) candesartan, (c) olmesartan and (d) valsartan.
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and their ARB partition coefﬁcient with respect to its aqueous environ-
ment [20], especially in the ﬂuid state, resembles that of natural plasma
membranes of the vasculature [8,9]. Phosphatidylcholine bilayers at
low temperatures occur in the lamellar gel phase (Lβ′) and at higher
temperatures in the liquid-crystalline phase (Lα). The transition is ac-
companied by several structural changes in the lipid molecules as well
as systematic alteration in the bilayer geometry, for example the
trans–gauche isomerization taking place in the acyl conformation. The
average number of gauche conformers indicates the effective ﬂuidity,
which depends not only on the temperature, but also on perturbation
due to the presence of a drugmolecule intercalating between the lipids.Fig. 2. DSC thermal scans with 2.5 °C/min for samples with different DPPC/candesartan
cilexetil (TCV-116) molar ratios. From top to bottom the TCV-116 concentrations are
x=0, 0.01 (1 mol% TCV-116), 0.05, 0.10 and 0.20. At 10 and 20 mol% the TCV-116 in-
corporation splits the main transition into two components (cp. Table 1).It is more and more evident that drugs affect the lipid membrane
core and may induce the formation of microdomains that modulate
the activity of proteins, thus offer a new avenue in the membrane-
lipid therapy. Representative examples are the drug:membrane inter-
actions of the β2 agonists indacaterol and salmaterol, which are char-
acterized by different pharmacological properties. It was suggested
that the synergy between the higher partitioning of indacaterol into
microdomains and the faster membrane permeation of indacaterol
could explain the faster onset and longer duration of its therapeutic
effect with respect to salmaterol. The higher membrane ﬂuidizing ef-
fect of salmeterol may contribute to its lower intrinsic efﬁcacy com-
pared to indacaterol [21]. Other studies postulated that active drugs
do change the lateral pressure proﬁle in bilayers and hence, can affect
the behavior of membrane proteins [22,23]. These are just two exam-
ples of the numerous others given in the literature demonstrating
that every bioactive molecule can be characterized by its own special
ﬁngerprint, when it interacts with membrane bilayers [24].
In this context, our laboratory has initiated research activity to
study the effects of the ARBs losartan, valsartan, olmesartan and
candesartan in membrane bilayers [3,7,25–27]. Thus, the signiﬁcant
amount of work performed on AT1 receptor antagonists could also
serve for comparative studies and further elaboration of the function
of amphiphilic drugs in the cell membrane. In this study, the effects of
TCV-116 intercalated in DPPC membranes were investigated, and
then were compared with the effects of its active metabolite
CV-11974 and other AT1 receptor antagonists. It is of importance to
investigate how the membrane effects of prodrugs are related to
their active metabolites in order to understand: (i) if prodrugs admin-
istered at the site of action may exert a more beneﬁcial proﬁle than
their active metabolites drugs, and to check (ii) if they exert similar
or differential, maybe more desirable perturbing effects at the mem-
brane interface.
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plementary methodologies has been put into practice, namely differ-
ential scanning calorimetry (DSC), Raman spectroscopy, small and
wide angle X-ray scattering (SAXS and WAXS), high-resolution liquid
nuclearmagnetic resonance (NMR) spectroscopy, solid state stationary
31P NMR and 13C cross-polarization magic-angle spinning (CP/MAS)
NMR spectroscopy as well as molecular dynamics (MD) have been
applied. Further, an in-house CP 31P NMR simulation methodology
was implemented that elaborates an automated 7-parameter ﬁtting
method and considers the studied DPPC/water multilamellar bilayers
immobilized in the time scale of the NMR experiment. A detailed
description of the broadline CP 31P NMR simulations of fully hydrated
multilamellar DPPC dispersions has been recently published [26,28].
Brieﬂy, DSC provides valuable information on the thermalmodiﬁcations
that are caused by the presence of drugs in the membrane [29]. Raman
and X-ray diffraction experiments provide complementary structural
information, such as interdigitation effects of the molecules in lipid
bilayers [30,31]. Performed solid state NMR experiments included 13C
MAS and 13C CP/MAS spectroscopy which offer useful information
for the dynamic changes that drugs cause when they are incorporated
in the lipid bilayers [32–35]. Typical observations are related with
chemical shift or intensity changes of various key atoms which are
partitioning in the membrane. Chemical shift changes are further asso-
ciated with phase transition properties of themembrane bilayer. More-
over new peaks arise because of the presence of the drug. Molecular
dynamics (MD) experiments provide useful information on the incor-
poration, localization and orientation of the drug molecule in the lipid
bilayers [36].
2. Materials and methods
2.1. Sample preparation
Dipalmitoyl-phosphatidylcholine (DPPC) was purchased from
Avanti Polar Lipids (Birmingham, AL), and used without further puri-
ﬁcation. Candesartan cilexetil (TCV-116) was kindly provided by
Medochemie Hellas A.E. (Pharma Cypria). The preparation of
multilamellar vesicles was done as described recently [25]. For DSC
experiments portions of ~5 mg from 50% (w/w) liposomal disper-
sions were used. The same preparation was carried out for the
Raman spectroscopy measurements. For X-ray scattering experi-
ments aqueous dispersions of multilamellar vesicles were prepared
with a ﬁnal concentration of 50 mg/mL (5% w/w). For solid state
NMR spectroscopy experiments 50% (w/w) liposomal dispersions
were used. The drug concentrations used were x=0.01 (1 mol%
candesartan cilexetil), 0.02, 0.05, 0.10 and 0.20.
2.2. Differential scanning calorimetry (DSC)
The samples obtained as described in the Materials section were
transferred to stainless steel capsules obtained from Perkin-Elmer
and sealed. Thermal scans were obtained on a Perkin-Elmer DSC-7 in-
strument (Norwalk, CT). All samples were scanned from 10 to 60 °C
at least three times until identical thermal scans were obtained
using a scanning rate of 2.5 °C/min. The following diagnostic param-
eters were used for the study of drug to membrane interactions: Tm
(maximum position of the recorded heat capacity), ΔTm1/2 (the full
width at half maximum of the phase transition), and the enthalpy
change, ΔΗ. Further experimental details are given in [25].
2.3. Raman spectroscopy
Raman spectra were recorded with a Perkin-Elmer GX Fourier
Transform spectrometer (Shelton, CT). A diode pumped Nd:YAG
laser at 1064 nm (Norwalk, CT) was used as the excitation source.
The scattered radiation was collected at an angle of 180° with respectto the incident beam. Spectra were recorded at a laser power of
400 mW on sample with a resolution of 2 cm−1. Raman spectra of
the examined samples were obtained in the frequency region of
3500–400 cm−1 and in the temperature range of 25 to 50 °C. Further
experimental details are described in [27].
2.4. Small and wide angle X-ray scattering
SAXS experiments were carried out at the Austrian SAXS beamline
(Elettra Laboratory, Sincrotrone Trieste, Italy) [37]. A linear
one-dimensional gas detector was used covering the q range (q=4π
sinθ /λ; where 2θ is the scattering angle and λ=1.54 Å the selected
X-ray wavelength) between 0.01 and 0.6 Å−1. Further details on the
set-up are found in [25].
Background corrected SAXSpatternswere analyzed in the full q-range
allowing the application of themodiﬁed Caillé theory [38,39]. The bilayer
model used and its applications have been recently presented [40]. From
the ﬁts to the scattered intensities I=S(q) |F(q)|2/q2 (S(q): structure fac-
tor; F(q): form factor) we directly obtained the lamellar repeat distance d
and the headgroup-to-headgroup thickness, dHH. The width σH of the
Gaussian peak applied tomodel electron density proﬁle of the headgroup
region was ﬁxed to 3 Å.
The effective lateral area per molecule was determined from





where x denotes the TCV-116 concentration. V is the effective molec-
ular volume (see below Eq. (3)) and dLuzzati is the membrane thick-
ness that is deﬁned by the Gibbs dividing surface [41]. Note that for
pure PC bilayers in the ﬂuid phase dLuzzati has nearly the same value
as dHH [42]. In the case of a linear dependence of A(x) one can extract
estimates for the partial molecular areas ADPPC and ATCV-116 by the re-
lation [43]:
A xð Þ ¼ x⋅ATCV−116 þ 1−xð Þ⋅ADPPC : ð2Þ
For the studied binary DPPC/TCV-116 formulations the effective
volumes were estimated using:
V xð Þ ¼ x⋅VTCV−116 þ 1−xð Þ⋅VDPPC ð3Þ
with VTCV-116=740 Å3 (the bare volume was estimated from losartan's
density in the solid state ρ=1.37 g/cm3 and its molecular weight
MW=610.66 g/mol), and the values of VDPPC=1228 Å3 (T=50 °C)
are taken from ref. [42]. Application of the bare volume of candesartan
cilexetil assumes that its insertion does not lead to a condensation of
the membrane. If condensation takes place, then VTCV-116 is expected
to become smaller than 740 Å.
An attempt to estimate computationally the VTCV-116 volume was
performed using the semi-empirical quantum chemistry package
MOPAC 2009. Before the calculation of the volume, the structure of
candesartan cilexetil was fully optimized using the PM6method included
in MOPAC 2009 package [44–46]. The PM6 method was chosen for the
geometry optimizations since it offers a good balance between speed
and accuracy. A recent paper highlighted the quality of predictions
obtained by PM6 method as similar to that of models based on B3LYP
[47]. For the optimized structure we have calculated the volume using
COSMO included in MOPAC 2009 package. COSMO (COnductor-like
Screening MOdel) is a computational method for determining the elec-
trostatic interaction of a molecule with a solvent. COSMO is a continuum
approach where the solvent is approximated by a dielectric continuum
surrounding the solute molecules outside of a molecular cavity. The
method was proven to be computationally efﬁcient and accurate [48].
The calculation of the volume was performed under several environ-
ments and different conformations. More speciﬁcally, we have ﬁrst esti-
mated the volume in the presence of gas, water, methanol, DMSO and
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717, 731, 730, 733 and 730 Å3. All these values are very close to the esti-
mation based on the solid state density (740 Å3) except for the volume
measured in the presence of gas. In order to further examine the system,
we have continued our study by producing several conformations of
candesartan cilexetil using the Balloon software [49]. The average esti-
mated volume in the presence of water for the ﬁve ﬁrst conformations
was 736 Å3 which is very close to the experimental value.
2.5. Nuclear magnetic resonance (NMR) spectroscopy
2.5.1. High resolution liquid NMR
Spectra of candesartan cilexetil were recorded on a Varian 600 MHz
spectrometer at 25 °C using a sample concentration of 20 mM. All data
are collected using pulse sequences and phase-cycling routines provided
in the Varian libraries of pulse programs. Further experimental details
and applied protocols are described in [7].
2.5.2. 13C Magic angle spinning NMR spectroscopy
Magic angle spinning (MAS)without or with cross polarization (CP)
was carried out on the samples described in the Sample preparation
section. The samples were transferred to 3.2 mm zirconia rotors. 13C
NMR spectra were obtained at 150.80 MHz with a 600 MHz Varian
spectrometer (Palo Alto, CA). The spinning rate usedwas 5 kHz. The ex-
perimental temperatures used were 25 °C, 35 °C, 45 °C for 13C-CP/MAS
experiments and 45 °C for the 13C-MAS measurement.
2.5.3. Solid state 31P CP NMR measurements
Solid state 31P CP NMR spectra of DPPC with or without candesartan
cilexetil were obtained on a Bruker (Karlsruhe, Germany) MSL 400
NMR spectrometer operating at 161.977 MHz and capable of high-
power 1H-decoupling. Each spectrum was an accumulation of 1000
scans. The standard pulse sequence of the Bruker software for the CP ex-
periment was used with the following acquisition parameters: recycling
delay 4 s, contact time 5 ms, acquisition time 1 ms, π/2 pulse for proton
7 μs. The contact time was chosen to give optimal spectra after testing
at 1, 3 and 5 ms. The temperature range used in the experiments was
25–50 °C. The sample was revolved in a 4-mM rotor at a low frequency
of 25 Hz.
2.6. 31P CP NMR simulations
The developed model assumes the lipid molecules to perform fast
overall rotational diffusion in both the liquid crystalline and in the
more organized gel phase. Both phases exhibit long range orientation
order, but the gel phase possesses in addition long range translational
order. The latter two properties are intimately related to the concept
of the packing quality of the lipids in the bilayer. Overall uniaxial ro-
tations, ﬂuctuations or wobbling of the axis of rotation, internalTable 1
Thermodynamic parameters of pure DPPC and with candesartan cilexetil (TCV-116) in-
corporated at molar ratios of x=0.01 (1 mol% TCV-116), 0.05, 0.10 and 0.20. Total













DPPC (x=0.0) 35.5 1.0 1.20±
0.03
41.2 1.0 7.89±0.08
DPPC/TCV-116 (x=0.01) 33.9 1.8 0.28±
0.04
40.5 1.15 7.88±0.08
DPPC/TCV-116 (x=0.05) – – – 40.1 1.33 8.61±0.09













9.97±0.10rotations, and lateral diffusion within the plane of the bilayer are mo-
tions of the lipid molecules subjected to the restrictions posed by the
anisotropic environment of the bilayer. All simulations were obtained
imposing Lorentzian spin packets, and the experimental spectra were
simulated by automated ﬁtting using the downhill simplex algorithm
with a convergence criterion of 0.01 [26]. The ﬁtting method com-
putes certain parameters from which the following described below
were used to extract information regarding the interactions of sartan
molecules with the DPPC bilayers.
The isotropic chemical shift, σiso, is characterized by the chemical
shielding tensor which corresponds to the easily recognized average
spectral and is deﬁned as the trace of:
σ iso ¼ σ xx þ σyy þ σ zz
 
=3: ð4Þ
The inhomogeneous broadening, Δσ, also named the residual an-
isotropy of the chemical shielding (CS) tensor, is related to the inter-
nal structure of the polar head group and corresponds to the total
width of the broadline. Ιt is indirectly correlated to the orientation
obtained by the axis of rotation of the lipids with respect to the CS
principal frame. The homogeneous broadening of spin packets, brd,
is caused by the dipolar 1H–31P interaction of the phosphorous with
the neighboring methylene protons. The collective tilt angle, ΘDR,
was determined by the director D, and the long axis of the phospho-
lipid molecules. This angle refers to the collective tilt of the lipids and
is related to the long-range orientational order of the bilayer. For fur-
ther details refer to [26].
2.7. Molecular dynamics of lipid bilayers
A bilayer of 72 DPPC molecules was simulated in the full-atom
representation under the CHARMM 36 force ﬁeld [50,51], in contact
with a water phase of 2162 water molecules described by the TIP3P
[52] (transferable intermolecular potential 3P) model. An equilibrat-
ed structure of the bilayer was provided as a PDB ﬁle by the Laborato-
ry of Molecular and Thermodynamic Modeling at University of
Maryland. Regarding to the candesartan cilexetil prodrug, its topolo-
gy ﬁle was made with the SwissParam server program [53] that pro-
vides topology ﬁles in GROMACS format, based on Merck molecular
force ﬁeld (MMFF) [54] in a functional form that is in compatibility
with the CHARMM force ﬁeld. It is also worth mentioning that
MMFF reproduces accurately bond lengths, bond angles and vibra-
tional frequencies in comparison with experimental data [53,54]. An
additional reason for choosing the above-mentioned server was the
extensive successful tests reported in reference [53] about small or-
ganic molecules into biomolecules which were described by
CHARMM force ﬁeld [55]. All simulations were performed with the
molecular dynamics package GROMACS 4.5.4 (see ref. [54] and there-
in) in the NPzAT ensemble with a constant area per lipid, A, equal to
0.64 nm2/lipid whereas the equations of motion were integrated
with a time step equal to 2 fs. Temperature was kept constant at
50 °C using the Berendsen thermostat [56] with a coupling time con-
stant equal to 0.1 ps whereas the Berendsen barostat [56] was
employed for the pressure coupling along the z-axis at 1 bar with a
coupling time constant equal to 1 ps. As far as the long range electro-
static interactions are concerned, they were treated with the particle
mesh Ewald (PME) method [57] while Coulomb and Lennard–Jones
interactions were calculated using a 1.0 nm cut-off radius. The system
was initially energy-minimized using the steepest descent method
and after that the MD simulation was started. The duration of the
MD simulation equals to 120 ns while the last 40 ns were used for
the computation of the selected properties.
The potential of mean force (PMF) of the candesartan cilexetil
from water to lipid phase was computed by a set of umbrella sampling
simulations with the reaction coordinate, ζ, to be the z-axis (ζ=0 for
the bilayer center). To this end, a harmonic potential (k=500 kJ/mol/
Fig. 3. (a) I1090/I1130 ratio vs. temperature plots for pure DPPC (solid squares) and DPPC
containing x=0.20 of candesartan cilexetil (open circles) are shown. In panel (b) the
corresponding I2850/I2880 and (c) the I2935/I2880 ratios are depicted. The pre-transition
temperature, Tpre, and main transition temperature, Tm, are marked with arrows on
the abscissa, while the transition temperatures, TI and TII for the DPPC/TCV-116 sample
are marked on the respective plots (cp. Fig. 2 and Table 1).
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windows were used for the biasing molecular dynamics simulations.
The distance for each window was deﬁned between the centers of
mass of the bilayer and drug. In particular, the PMF was computed
by the weighted histogram analysis method (WHAM) [58,59] that is
available in GROMACS. These computations were done in an extend-
ed system that contains 3020 water molecules so as to avoid the in-
teraction of the drug with the periodic image of the opposite leaﬂet
of the bilayer. The protocol we followed is according to the umbrella
sampling simulations reported in references [60,61]. The duration of
the thirty three biasing simulations is 20 ns in which the ﬁrst 5 ns
are regarded as equilibration while the rest parameters are exactly
the same with those reported in the previous subsection. Preferable
conﬁgurations of the candesartan cilexetil in the DPPC bilayer were
determined applying a clustering algorithm that is available in the
UCSF Chimera software [62].
3. Results
3.1. Differential scanning calorimetry
The thermal changes in the pure DPPC/water system as well as the
inﬂuence of different concentrated inclusions of TCV-116 in DPPC bi-
layers are shown in Fig. 2. In pure DPPC (top curve) two characteristic
endothermic peaks are visible referring to the pre- and the main tran-
sition, respectively. The DPPC molecules form below the pre-
transition the well organized lamellar gel phase, Lβ′, while above the
main transition temperature the ﬂuid lamellar phase, Lα, is apparent.
An intermediate phase, Pβ′, is also observed, in which the bilayers are
modulated by a periodic ripple (ripple phase). The recorded transi-
tion temperatures and enthalpies are in good agreement with litera-
ture values [10] (Table 1). The insertion of TCV-116 at 1 mol%
almost abolishes the pre-transition and shifts it to a lower tempera-
ture. It affects also the main transition by increasing its width and
shifting it to a lower temperature by 0.7 °C (Table 1). The presence
of TVC-116 at this low concentration affected only the enthalpy
change; ΔΗ, of the pre-transition by lowering its value about 4
times. When 5 mol% of the prodrug is incorporated, the pre-
transition was abolished and the main transition was further shifted
to lower temperature while its width further increased. TVC-116 at
this concentration caused a ΔΗ increase of the main phase transition
(Table 1). At higher concentrations (10 and 20 mol%) TVC-116 caused
extensive broadening of the phase transition with two distinct maxi-
ma (at TI and TII) and a further increase of the total enthalpy, ΔΗ, of
the main phase transition (Table 1).
3.2. Raman spectroscopy
Raman spectra of pure DPPC bilayers in the presence of 20 mol%
TVC-116 were obtained in a temperature range of 27–50 °C. The tran-
sition behavior was especially characterized by the C\H and C\C
stretching modes changes.
The C\C stretching mode region in the spectral interval of 1050–
1150 cm−1 reﬂects directly intramolecular trans–gauche conforma-
tional changes within the hydrocarbon chain region of the lipid ma-
trix [17,18]. Fig. 3a shows the changes in the I1090/1130 intensity ratio
caused by TVC-116 when incorporated into DPPC bilayers. The transi-
tion temperatures of pure DPPC bilayers compare well to the results
found from the calorimetric measurement (cp. Fig. 2, Table 1), how-
ever, at x=0.20 the two main transition components, at TI and TII,
are not resolved by the I1090/1130 intensity ratio, instead a rather con-
tinuous increase in the I1090/1130 intensity ratio is observed. The effect
of TVC-116 is quite signiﬁcant: ﬁrst, the ﬂuidity in the gel phase is
slightly increased (from about 0.68 to 0.78), and secondly, the trans
to gauche isomerizations change strongly, i.e. the intensity ratio
drops from 1.5 to 0.9 at 50 °C (60% decrease).Themost intense bands in the Raman spectrumare those attributed to
themethylene C\H stretchingmode region from 2800 to 3100 cm−1. In
particular, the symmetrical and antisymmetrical methylene stretching
bands allow investigating phase transition behaviors. The intensity ratio
of these two bands I2845/2880 describes the main changes occurring in
the hydrocarbon chain region. This ratio is sensitive to subtle changes in
conformational order from rotations, kinks, twists and bends of the lipid
chains [63]. Similar to the ﬁndings for the I1090/1130 ratio, in the gel
phase regime the I2845/2880 values are slightly higherwith the intercalation
of the drug, but the intensity ratio is clearly reduced in the ﬂuid phase
regime in the presence of TVC-116 indicating a strong reduction in
chain disorder (Fig. 3b). The intermolecular lipid chain interactions of
the lipids can be elicited from changes in the 2935/2880 peak height in-
tensity ratio that measures the effects originating from changes both in
interchain order and intrachain order–disorder processes. The I2935/2880
ratio constitutes a sensitive probe to monitor the lipid phase transitions
despite the fact that the C\H stretching mode region consists of many
superimposed vibrational transitions [64–66]. In the pure DPPC disper-
sion, again the pre- as well as main transitions are clearly displayed
Fig. 4. X-ray scattering curves of DPPC/TCV-116 multilamellar vesicles at 20 °C and 50 °C (a), and their corresponding electron density proﬁles (b). In panel c the WAXS peak arising
from the hexagonal chain packing is plotted. The full red lines in panels a and c give the best ﬁt to the data (cp. Table 2).
Table 2
Structural data on pure DPPC bilayers and DPPC membranes with 20 mol% (x=0.2)









d (Å) 63.5a 67.0a 71.8 67.3
dHH (Å) 44.2a 38.3a 43 37
d-dHH (Å) 19.3a 28.7a 29 30
A (Å3) 47.9 (20.3)a 64a 48b (20.5) 64/46c
σ (Å) 1d 6e 8 8
a Structural data taken from the review [42].
b The area per lipid in the gel phase was calculated under the assumption of a chain
conserved chain tilt.
c The partial areas ADPPC and ATCV-116 were obtained applying Eq. (2) and refer to
Fig. 5d.
d Estimated values from the global data analysis applying the paracrystalline theory.
e Data concerning the root mean square ﬂuctuation in pure DPPC rely on data from
references [68,75].
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smooth andmonotonous increase of I2935/2880 can be seen. Also the overall
intensity changes, ΔI, are far smaller (ΔI=0.30 compares to ΔI=0.12;
Fig. 3c).
Other characteristic band alterations give evidence for the incor-
poration of TCV-116 in the DPPC bilayers (data not shown). First, an
additional band around 1600 cm−1 was observed, which is attributed
to the aromatic C_C stretch. The above mentioned band was ob-
served also in bilayers containing the AT1 receptor antagonist
CV-11974. The presence of additional aromatic peaks characteristic
of their incorporation was observed for CV-11974 (Fig. 1b) at
800 cm−1 and at 1024 cm−1 for olmesartan (Fig. 1c), another mem-
ber of the sartans family [7,27]. Second, the band at 714 cm−1 corre-
sponding to C\N stretch vibration, showed a shift to higher values,
when TCV-116 is present in the membrane. This indicates that
TCV-116 interacts with headgroups. Third, TCV-116 caused a shift
and line-shape changes at 1296 cm−1 which correspond to
stretching vibrations of the (CH2) region of the DPPC bilayers. This
is a direct evidence of the interaction of TCV-116 with (CH2) region
of the DPPC bilayers.
3.3. Small and wide angle X-ray scattering
In Fig. 4 are shown the scattering patterns of DPPC bilayers in the
presence of x=0.2 TVC-116 at 20 and 50 °C, respectively. As com-
monly observed for sartans [25,27] an increased stacking disorder in
the multilamellar vesicles (MLVs) is observed also in the presence
of TVC-116. This disorder is stronger in the gel-phase. In the bottom
scattering pattern of Fig. 4a (20 °C), mainly form factor contributionsare present accompanied only by a weak ﬁrst order diffraction peak at
q=0.08 Å−1. Both SAXS patterns have been analyzed by global ﬁtting
procedures [19], and best ﬁts are displayed by solid red lines. The cor-
responding electron density proﬁles are displayed in Fig. 4b, and the
most important structural parameters as well as the membrane ﬂuc-
tuation parameter σ are summarized in Table 2. Note that for the gel
phase σ(gel) is deduced from the paracrystalline theory for lattice
disorder of second type [67], i.e. practically ﬂat bilayers are consid-
ered to oscillate with respect to the neighboring membranes, while
for the ﬂuid phase σ(ﬂuid) [68] is deduced from the application of
the modiﬁed Caillé theory [38,39]. In the later theory also bilayer
Fig. 5. Bilayer parameters of DPPC at 50 °C in dependence of candesartan cilexetil con-
centration. a: d-spacing, b: head to headgroup distance, dHH, c: water layer thickness,
d-dHH, d: effective area per molecule, A, and e: effective molecular volume.
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candesartan cilexetil are the loose stacking in the gel-phase as
evidenced by the large interstitial water layer (Δ(d-dHH)=+9 Å
and Δσ=+7 Å; Table 2) and the enhanced diffuse scattering due
to positionally uncorrelated membranes (unbound state). The lipid
chain packing area AC at 20 °C was retrieved from the (20) and (11)
reﬂections according to Sun et al. [69]. The ﬁtted d-values d20=
4.24 Å and d11=4.18 Å compare well to the literature values found
for pure DPPC [69], however, the expected orthogonal chain packing
is not undoubtedly expressed in the diffraction pattern, and hence
we alternatively ﬁtted also a single Bragg peak centered at q=
1.5 Å−1 (Fig. 4c). In both cases the determined chain packing area
AC is virtually the same as for pure DPPC bilayers (Table 2). This alsoholds true for the area per lipid, but only under the assumption of
conserved chain tilt. In the ﬂuid phase the bilayer swelling and in-
crease of membrane ﬂuctuation parameter are less pronounced
(Δ(d-dHH)=+1.3 Å and Δσ=+2 Å; Table 2).
Further, the inﬂuence of candesartan cilexetil in the ﬂuid phase at
50 °C was examined in a concentration range from x=0 to 0.20. The
main results from the SAXS experiments are given in Fig. 5. Apart
from the interbilayer distance at 10 mol% drug concentration all
other derived structural results follow monotonous trends as a func-
tion of x. The induced membrane thinning from 38.3 to 37.0 Å
(ΔdHH~1.5 Å; Fig. 5b) is accompanied by a steady increase in the
water spacing, d-dHH (Fig. 5c). Also the effective area per molecule,
A, displays an almost linear behavior (Fig. 5d). This suggests that
candesartan cilexetil does not affect the lateral area of DPPC signiﬁ-
cantly and allows us to estimate the partial molecular areas for
DPPC and candesartan cilexetil applying Eq. (2) (solid line in
Fig. 5d). ADPPC results in 64 Å2±1 Å2 and ATCV-116=46±3 Å2. ADPPC
is well in agreement with literature data [42]. In Fig. 5e the estimated
effective volumes per molecule are shown. They are calculated from
the partial volumes as speciﬁed in the Material and methods section.
3.4. NMR spectroscopy
3.4.1. High resolution liquid NMR proﬁle
TCV-116 was dissolved in deuterated dimethyl sulfoxide solvent
(d6-DMSO) that provides an amphiphilic environment reported to
mimic the physiological environment of membrane bilayers [70]. The
structure elucidation of TCV-116 is required for two reasons: (i) it con-
ﬁrms the purity and identity of the prodrug under study; (ii) it explains
the additional 13C signals in the 13CP/MAS experiments attributed to the
incorporation of the drug.
The unambiguous drug structure identiﬁcation of TCV-116 has
been achieved using 1D and 2D homonuclear and heteronuclear
NMR experiments (see in Supplementary Materials Fig. S1 and Table
S1 as well as a brief description), and previous reported work on
the structural and conformational analysis of other AT1 receptor an-
tagonists, especially candesartan (CV-11974) and synthetic analogs
[7,71–73].
3.4.2. 13C Magic angle spinning NMR spectroscopy
To obtain detailed local information on the incorporation of
candesartan cilexetil in the DPPC bilayers, high-resolution solid-
state NMR spectroscopy was applied using magic angle spinning
(MAS) with and without cross polarization (CP).
In Fig. 6 the CP-MAS spectra are displayed for 25, 35 and 45 °C.
Each spectrum is divided into three regions, namely referring to the
carbon atoms in the (i) hydrophobic region (10–40 ppm), to those
in (ii) headgroup, glycerol backbone regions and region containing
carbons between aromatic segments (55–80 ppm) and (iii) to the ar-
omatic and esteriﬁed carbonyls (125–180 ppm).
At 25 °C, candesartan cilexetil caused a signiﬁcant broadening in
the line width of the observed peaks. In addition, some broad and
barely observable peaks are detected in the aromatic region, which
reﬂects the incorporation of candesartan cilexetil in the DPPC bilay-
ers. This signiﬁcant broadening in the presence of candesartan
cilexetil results in the absence of features commonly seen in the ali-
phatic peaks resonated between 14 and 33 ppm. At 35 °C, the same
conclusions can be derived. At 45 °C the specimen of DPPC/TCV-116
bilayers again displays a set of broad peaks that resemble those of
the lamellar gel phase and ripple phase. In contrast, the pure DPPC bi-
layers show the well known sharpening of all the peaks as the tem-
perature is greater than Tm. We note that the MAS spectrum at
45 °C without cross polarization was not informative, since the sam-
ples of DPPC alone and DPPC/TCV-116 provided almost identical
spectra (see Supplementary Materials, Fig. S2). Table S2 (Supplemen-
tary Materials) shows in detail the observed chemical shifts for DPPC
Fig. 6. 13C-CP MAS spectra at 25 °C, 35 °C and 45 °C for pure DPPC (black lines) and DPPC/TCV-116 bilayers (red lines: 20 mol% TCV-116).
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13C-CP/MAS and 13C-MAS experiments. This includes listings of the
additional peaks attributed to candesartan cilexetil.3.5. Simulations of broadline 31P NMR spectra
Experimental and simulated 31P NMR spectra of DPPC and DPPC
loaded with candesartan cilexetil bilayers have been obtained at as-
cending 2 °C in the temperature range of 25–50 °C (Fig. 7). Several
conclusions can be drawn by studying the experimental and simulat-
ed spectra. The presence of the prodrug in the lipid bilayers (Fig. 7b)
has as a consequence (i) the modiﬁcation of the isotropic shift toward
lower values and (ii) the abolishment of the deep minimum observed
in the 31P NMR broadline spectra in gel phase. This minimum is espe-
cially prominent in pure DPPC bilayers above 30 °C (Fig. 7a). (iii) The
proﬁles of the spectra containing the prodrug do not change signiﬁ-
cantly with the temperature.
The spectral simulation parameters of unloaded and loaded DPPC
bilayers in the range of 25–50 °C are summarized in Table S3 (Supple-
mentary Materials), and their temperature proﬁles are further plotted
in Fig. 8 in order to extract information regarding dynamical and con-
formational characteristics of the bilayers that are affected by the in-
corporation of the drug. In particular, as presented in Fig. 8a, the
incorporation of TCV-116 molecules signiﬁcantly decreases the iso-
tropic chemical shift, σiso, due to the extra shielding provided to the
31P bilayer polar head.In Fig. 8b the effect of TCV-116 on the inhomogeneous broadening,
Δσ, is shown. Unloaded DPPC bilayers exhibit a signiﬁcant reduction
of Δσ in the range of 27–32 °C and a change in the slope at 33 °C (a
value that is close to the pre-transition temperature; cp. Fig. 2;
Table 1) suggesting the transition to another phase. Above 33 °C the
value of this parameter remains constant. The incorporation of
TCV-116 molecules differentiates the trend of this parameter indicat-
ing that the prodrug molecule disturbs the conformation of the
headgroup. The values of Δσ are signiﬁcantly higher in the case of
sartan loaded bilayers up to 43 °C. Above 43 °C the two preparations
have comparable Δσ values.
The homogeneous broadening temperature proﬁle (brd; Fig. 8c) of
unloaded bilayers decreases monotonically in the temperature range
of 25–35 °C indicating a signiﬁcant increase of the mobility of the
bilayer as temperature increases. In the preparation containing
TCV-116 the decrease is monotonous but not as steep. In addition,
the homogeneous broadening values above 33 °C are always higher
than the respective ones containing no prodrug. In the liquid crystal-
line state the brd values of the DPPC/TCV-116 preparation are signif-
icantly lower as compared to the ones of pure DPPC bilayers.
The temperature proﬁles of collective tilt, ΘDR, of unloaded and
loaded bilayers are displayed in Fig. 8d. The changes in the slope of
these proﬁles occur approximately at 35 °C and 43 °C (values close
to the pre-transition and the main transition temperature, respective-
ly; cp. Fig. 2 and Table 1), thus ascertaining the existence of three la-
mellar phases. In the temperature range of 25 to 33 °C and 43 °C to
50 °C the ΘDR values of unloaded bilayers are higher in comparison
Fig. 7. Experimental (solid lines) and simulated (dashed lines) 31P NMR spectra of
DPPC bilayers alone (a) and with candesartan cilexetil (x=0.2) (b) in the temperature
range of 25–50 °C.
Fig. 8. Temperature dependence of the key ﬁtting parameters of the 31P NMR spectra of
pure DPPC bilayers (solid squares) and DPPC membranes with candesartan cilexetil
(x=0.2) (open circles) in the temperature range of 25–50 °C: (a) Isotropic chemical
shift, σiso, (b) residual anisotropy, Δσ, (c) homogeneous broadening, brd, and (d) col-
lective tilt angle, ΘDR. Note, the dashed red lines (polynomials) are only given to
guide the eye.
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containing TCV-116 have higher values.
3.6. Molecular dynamics
Our analysis starts with the density proﬁles of all components
along the z-axis which is normal to the two DPPC leaﬂets. The
TCV-116 was placed initially in the water phase and in the course of
the simulation, it penetrated into the bilayer. The exact distribution
of all components is given in Fig. 9a, in which it is clear that the
drug prefers being in the interior of the DPPC bilayer. Within a simu-
lation time of 40 ns the distance of the drug center with respect to the
bilayer center is in average 1 nm (Supplementary Materials, Fig. S3).
Furthermore, this way crossing events can be checked (i.e., the migra-
tion of the drug from the one leaﬂet to the other) during the course of
the simulation. In this case, the drug did not cross through the middle
of the bilayer to reach the opposite leaﬂet.
As described in the Materials and methods section, umbrella sam-
pling simulations were conducted in order to compute the potential
of mean force (PMF) of the candesartan cilexetil from the water to
lipid phase (see Supplementary Materials Fig. S4). In accordance
with the mass density proﬁle of candesartan cilexetil (Fig. 9a), the
global minimum is found at 1 nm distance from the bilayer midplane.Note that the drug was initially placed in the water phase and then
penetrated to the position indicated by the PMF. Another interesting
observation is the energy barrier (+14.7 kJ/mol) around the middle
of the bilayer that has to be overcome from candesartan cilexetil to
reach the opposite leaﬂet. In addition, the free energy for partitioning
into the membrane was computed by the difference of PMF at large
distances and at the location of the minimum. This value is approxi-
mately equal to −50.7 kJ/mol. Also, there is a linear region in the
PMF, which is characterized by a large attractive force toward the in-
terior of the bilayer, and its slope equals to 37.6 kJ/mol/nm. The afore-
mentioned region ends at a constant value of PMF that corresponds to
the water phase which is not affected by the presence of the bilayer.
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ment in the drug during the umbrella sampling simulations. In gener-
al, cylindrical conﬁnement leads the molecule to adopt less number of
states, increasing thus the accuracy of the estimated free energy pro-
ﬁle. An excellent study for umbrella sampling simulations of mole-
cules in a lipid bilayer is given in reference [74].
Due to the position of the drug in the bilayer, it is expected a
strong interaction with the DPPC–water interface through hydrogen
bonds. Indeed, there are hydrogen bonds between the TCV-116 and
the other components of the system (water and DPPC) and particu-
larly the number of hydrogen bonds with DPPC and water is 0.633Fig. 9. Molecular dynamics simulation on the interaction of candesartan cilexetil with
DPPC bilayers. (a) Mass density proﬁles of water (black), DPPC bilayers (blue) and
candesartan cilexetil (TCV-116) (red) are presented. On top two representative lipid
molecules of the bilayer are depicted schematically. Most representative structures of
the candesartan cilexetil in the DPPC membrane are shown in panels B and C. The
membrane plane is parallel to the x, y-axes, i.e. its normal coincides with the z-axis.and 2.151, respectively. The most preferable conformations of the
TCV-116 in the DPPC bilayer are depicted in Fig. 9B and C. Here two
representative conformers are depicted in decreasing order.
4. Discussion
4.1. Lipid conformational changes and formation of domains
The phase behavior of pure DPPC is very well documented [75].
Brieﬂy, multilamellar vesicles of DPPC in excess of water undergo an
endothermic melting transition, in which the van der Waals interac-
tion energy accounts for 63% of the total enthalpy and changes in
rotamer energy amount to 32% [76]. The intermediate ripple phase
formation is commonly related to the coexistence of alternating
ﬂuid- and gel-like domains [77,78], but alternative models describingthe Pß′ phase built up by a single gel phase have also been put forward
[79].
The most striking result of the DSC experiments is that the main
transition splits into two components at high TCV-116 concentrations
(x=0.10 and 0.20), which is most probably caused by the formation
of prodrug rich and poor domains. Interpreting the incorporation of
the prodrug as a membrane impurity, it is most likely that the low
temperature component (I) is caused by the melting of TCV-116
rich domains, whereas the higher temperature component (II) is
due to the melting of TCV-116 poor domains (Fig. 2, Table 1). This
view is supported by the fact that the enthalpy of component (I) be-
comes dominant at the highest drug concentration. A very similar be-
havior was found also for losartan [3,80], irbesartan [81], and
valsartan [25], whereas olmesartan [27] and the CV-11974 [7] do
not induce any splitting of the main transition. Moreover, the latter
two sartans are not able to suppress the pre-transition (up to x=
0.20), while all other studied sartans do suppress the pre-transition
above a drug concentration of 5 mol% [3,25,80,81]. This also means
that olmesartan and candesartan are not disturbing the lipid chain
packing in the gel-phase signiﬁcantly.
As expected from calorimetric measurements TCV-116, as also
losartan [7] and valsartan [25], inﬂuences signiﬁcantly the analyzed
Raman ratios (Fig. 3). Interestingly, all three molecules: (i) do not dis-
play the pre-transition anymore; (ii) show slightly bigger ratios in the
gel-phase and (iii) signiﬁcantly smaller ratios in the ﬂuid-phase as
compared to pure DPPC vesicles. Referring to the gauche/trans ratio
(I1090/1135; Fig. 3A) this means that losartan, valsartan and TCV-116
enhance the bilayer ﬂuidity below the melting point, but decrease it
above Tm. Noteworthy, among all studied sartans TCV-116 shows
the strongest ability to reduce the gauche/trans ratio in the Lα phase
(see that ΔI1090/1130 drops from 0.84 to 0.22; Fig. 3A). On the contrary,
the Raman ratios of candesartan (CV-11974) [7] concerning the
gauche/trans ratio and chain mobility (reﬂected in I1090/1135 and
I2935/2880, respectively) do clearly display the pre-transition.
Candesartan has also little effect on the absolute values of the
Raman ratios in the gel-phase regime. However, the ﬂuidity of the bi-
layers in the Lα phase reduces signiﬁcantly (ΔI1090/1130 drops from
0.84 to 0.38). Similarly olmesartan does not disturb the chain packing
in the Lß′ phase, which was conﬁrmed by wide angle X-ray scattering
(WAXS) data [27], i.e., the common lipid chain packing on an orthog-
onal lattice is unaltered [69]. However, olmesartan [27] seems so far
the only sartan that is able to increase the ﬂuidity above the melting
point, presumably because its polar interactions are weakened due to
possible intermolecular hydrogen bonding between the carboxylate
and hydroxyl groups.
A further hint for TCV-116's ability to induce the formation of do-
mains at high drug concentrations (Fig. 2; x=0.1 and 0.2) is provided
by the wide angle X-ray diffraction (WAXD) data. In Fig. 4C the
recorded wide angle peaks reﬂect the lipid chain packing in the
gel-phase, but WAXD pattern at 20 °C displays neither a clear sym-
metric (hexagonal packing) [82] nor a convincing pattern typical for
a chain packing on an orthogonal lattice [69]. Thus, the chain packing
known from the pure Lβ′ phase [69] is not completely conserved,
when TCV-116 is incorporated into the bilayer. Recently, we reported
on similar effects found for the addition of valsartan [25]. Here the
chain packing appears on a hexagonal lattice, and further, the SAXS
pattern suggested the coexistence of bilayers with fully interdigitat-
ing non-tilted chains (LβI phase) with bilayer domains that conserve
the Lβ′ phase.
4.2. Prodrug-induced structural changes in the lipid bilayer
Even though DSC and WAXS data suggest the formation of
TCV-116 poor and rich domains, respectively, this is not conﬁrmed
by the SAXS data experiments. The data analysis of the SAXS pattern
at 20 °C indicates no drastic membrane thickness heterogeneity
Fig. 10. Schematic illustration of DPPC bilayer structure alterations induced by candesartan cilexetil (TCV-116). Without the drug the Lβ′ phase is present at 20 °C (a). The incor-
poration of 20 mol% TCV-116 induces a signiﬁcant swelling of the Lβ′ phase (b). Panel c demonstrates pure DPPC bilayers in the Lα phase at 50 °C. The same conditions with
20 mol% TCV-116 are given in panel d. Dimensions in all panels base on the structural data given in Table 2.
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one bilayer thickness only, i.e., the obtained bilayer thickness dHH=
43 Å is almost the same as found for pure DPPC (Table 2). This in
turn means that the prodrug-rich domains are unlikely to resemble
a fully interdigitated lamellar LβI phase (dHH~35 Å). However, the ob-
served increase in the main transition enthalpy at 20 mol% TCV-116
(Table 1), which is in the same order of magnitude as for losartan
[3,80] and valsartan [25], would instead support the assumption,
that also TCV-116 mediates at least partially chain interdigitation in
the gel-phase. This is supported by the fact that the enthalpy of the
interdigitated LβI to Lα phase transition is about 1 kcal/mol bigger as
compared to Lβ′ to Lα phase transition in PC systems [83].
In the ﬂuid phase, the incorporation of 20 mol% of TCV-116 does
not alter the bilayer structure much. The data are satisfactorily ﬁtted
with the common bilayer model [40] (Fig. 4a and b, upper curves),
and only a small reduction of the membrane thickness, dHH, from
38.3 to 37.3 Å is observed (Fig. 5b, Table 2). This membrane thinning
can be explained by the prodrug position in the monolayer leaﬂet (cp.
Fig. 9). Since the overall penetration depth of TCV-116 is signiﬁcantly
smaller than the lipid monolayer thickness, one opposing DPPC–
(TCV-116) pair in the bilayer is expected to span a shorter distance
than two opposing lipids, and hence the overall membrane thickness
reduces (see Fig. 5b and the schemes in Fig. 10). Obviously this effect
gains in inﬂuence with increasing prodrug concentration, but it is for
TCV-116 relatively small when compared to e.g. the membrane-
thinning effect of valsartan. At a prodrug concentration of 20 mol%
the membrane thickness decreases in ﬂuid PC bilayers only 2–3% in
the presence of candesartan cilexetil, whereas it reduces around 9%
in the presence of valsartan. Also the estimated partial area per
TCV-116 molecule is with about 46 Å2 relatively small in comparison
to the lipid area of DPPC (64 Å2). This means that the partial interdig-
itation of lipids is hindered in the ﬂuid phase and thus the membranethinning is expected to be relatively small. In contrast, valsartan has a
partial lateral area of 58 Å2 [25] that comes close to the lipid area of
DPPC. This favors partial interdigitation of DPPC lipids. Indeed the de-
termined membrane thinning induced by 20 mol% valsartan is 3–4
times bigger as compared to the effect seen with candesartan
cilexetil.
The observed increase in the intermembrane distances (Fig. 4,
Table 2), especially in the gel-phase, can be explained by the negative
surface charge density conferred to the bilayers upon TCV-116 insertion.
Due to its acidic center at the tetrazole group (Fig. 1a) with a reported
pKa value of 5.9 [84] about 90% of the molecules are expected to be neg-
atively ionized at neutral pH. This membrane repulsion force has also
been reported for all other studied sartans [25,27,81,85]. Their effective-
ness in unbinding membranes (i.e., the electrostatic repulsion of neigh-
boring membranes) depends solely on their pKa values. Ranking the
sartans in decreasing order of their pKa values, reﬂects perfectly their
membrane unbinding power, which increases in the order from
TCV-116→valsartan→ irbesartan→olmesartan→ losartan. While TCV-
116 causes only a modest increase of the equilibrium distance between
adjacent bilayers, losartan with the lowest pKa (2.95–3.14 [20,84])
causes complete unbinding of the membranes, i.e., the formation of
unilamellar vesicles both in the gel and ﬂuid phase of PCs [85].
4.3. Candesartan cilexetil's localization in lipid bilayers
MD calculations showed that prodrug TCV-116 prefers to locate in
the interior of DPPC bilayers. Hereby, the prodrug is attached with its
negatively charged tetrazole group with surrounding choline groups
of the phospholipids, while its hydrophobic groups span the upper to
middle segment of alkyl chains (Fig. 9a). Additionally, it exerts strong
interaction with the DPPC–water interface through hydrogen bonds. A
similar localization was observed also for other sartans [3,7,25–27,85].
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Siarhevera et al. showed using 2D NOESY 1H–1H MAS experiments
that even structurally rather diverse molecules had all their highest
concentration between the phosphate of the lipid headgroup and the
upper segments of the lipid hydrocarbon chains. Thus, amphiphilicmol-
ecules are commonly localized in the same topography of lipid bilayers
but still exerting different biological activity.
The ﬁrm anchoring of TCV-116 in DPPC bilayers is supported by
13C CP/MAS experiments. The DPPC/TCV-116 bilayer spectra contain
peaks with broad half-widths (Fig. 6). Such spectra are indicating re-
duced mobility in the system. As far as the AT1 receptor antagonists
are concerned a trend for the broadening of the peaks in the 13C CP/
MAS spectra could be identiﬁed: the bulkier the sartan is, the lower
the bilayer mobility becomes [3,7,27].
The σiso and brd temperature proﬁles (Fig. 8a and c) derived from
the simulations of the broadline 31P NMR spectra (Fig. 7) provide in-
formation on the sartan localization in the DPPC bilayers due to the
drug/membrane interactions. TCV-116 molecules clearly decrease
signiﬁcantly the isotropic chemical shift σiso due to the extra shielding
provided to the 31P of the headgroup. This indicates that TCV-116
molecules localize in the hydrophilic zone of the phospholipid bilayer
formed by the polar headgroups and the lipid–water interface, in
agreement with MD calculations (Fig. 9). Losartan insertion lowers
the σiso values (Fig. 8a): (−21 ppm) [7] more than the candesartan
[7] and TCV-116 molecules do (−20 ppm), indicating an even stron-
ger interaction of losartan with the polar headgroup with respect to
candesartan and TCV-116, at least in the liquid crystalline phase.
This may be attributed to the fact that losartan has a lower pKa
value [20,84], i.e., the fraction of negatively charged tetrazole groups
is greater at neutral pH, and thus, losartan is interacting stronger
with the positively charged choline groups of the surrounding DPPC
lipids (cp. also the discussion on membrane unbinding in Section 4.2).
The values of brd in TCV-116 loaded DPPC bilayers are higher
above 35 °C as compared to pure DPPC membranes (Fig. 8b), signify-
ing that the incorporation of this sartan inhibits the bilayer mobility.
Note, that this parameter is probably directly coupled to the mea-
sured chain mobility (see Raman ratio I2935/2880 in Fig. 3C), which is
also strongly reduced under the inﬂuence of TCV-116. Similar obser-
vations have been made for other studied sartans such as losartan
and candesartan [7]. The decreased bilayer mobility of sartan loaded
DPPC bilayers shows that drugs are localized close to the polar head
moiety and affect the dipolar 1H–31P interaction of the phosphorus
with the neighboring methylene protons. In the case of losartan, the
brd values are continuously decreasing up to 50 °C (no clear sign of
a pre- or main transition is apparent) reaching at about 50 °C the bi-
layer mobility of unloaded DPPC membranes (~2.5 ppm) [7]. In com-
parison CV-11974/DPPC [7] and TCV-116/DPPC bilayers display a
slightly smaller bilayer mobility (~3.5 ppm) at 50 °C, indicating
weaker dipolar 1H–31P interactions.
5. Conclusion and outlook
All AT1 receptor antagonists studied so far are accommodated in
the polar/apolar interface of the lipid bilayer. Such a localization for
amphiphilic molecules is not surprising and has been for instance
also reported for structurally rather diverse P-glycoprotein substrates
[86]. The ﬁndings in this work provide signiﬁcantly more information.
The results from different complementary techniques (DSC, Raman
spectroscopy, SAXS, WAXS, NMR, molecular modeling, and NMR sim-
ulation) are able to point out the complexity of the interactions of
each individual AT1 receptor antagonist with the plasma membrane.
(i) Each studied sartan causesmore or less an electrostatic repulsion
of neighboringmembranes and its strength depends solely on its
pKa (referring to the acidic tetrazole group). Hence losartan dis-
plays the strongest intermembrane repulsion [85], while thehere studied TCV-116 shows rather mild effects (Figs. 5c, 10).
(ii) As illustrated in Fig. 10D all studied sartans induce a bilayer
thinning in the Lα phase. The most decisive parameter for the
observed partial interdigitation of lipids is given in the partial
molecular area of the sartans. We observed that sartans with
molecular areas that come close to that of DPPC (64 Å2) induce
the strongest membrane thinning. For instance valsartan oc-
cupies an estimated molecular area of 58 Å2 in DPPC bilayers
and causes at 20 mol% drug concentration a thinning of 9%
[25]. Contrarily the molecular area of TCV-116 covers only
46 Å2 and consequently the membrane thinning effect (~1 Å)
is rather small.
(iii) The majority of sartans induce the formation of drug rich and
poor domains in the gel-phase regime. This concerns losartan
[3,80], valsartan [25], irbesartan [81] and TCV-116 (this work).
On the other hand, olmesartan [27] and the CV-11974 [7] do
not induce any formation of drug-rich and drug-poor domains,
i.e., no splitting of the main transition is observed in the
DSC-signal and the pre-transition gets only slightly disturbed.
(iv) All studied sartans except for olmesartan [27] decrease the ﬂuid-
ity (gauche/trans ratio) of the bilayers in the Lα phase. TCV-116
displays hereby the strongest effect of all so far studied sartans
(Fig. 3a).
Even though most amphiphilic drugs are anchored in the lipid/
water interface presumably maximizing their amphipathic interac-
tions, they do not exert identical membrane perturbations, but as
outlined above for the class of sartans, each drug is characterized in
principle by its own individual “ﬁngerprint”. If we hypothesize that
this ﬁngerprint is essential for the drug's action, then future rational
drug design should not only take into consideration direct drug action
at the active site, but also the speciﬁc drug–bilayer interactions in
order to forecast consequences in drug efﬁciency. This notion has
been also adopted by other research groups for various classes of am-
phiphilic drug molecules [4,5,87–89]. In this respect a two step model
was put forward for the action of AT1 receptor antagonists reaching
their active site by the “membrane pathway”, and such, ﬁnding a suit-
able environment to exert their action [3,81].
Direct binding scenarios of sartans shall also be considered in fu-
ture investigations. As outlined by Dror et al. in this binding pathway
drugs encounter twomajor barriers: the “expected” barrier suggested
by receptor geometry, proximal to the binding pocket, and also an
“unexpected”, earlier barrier at the receptor surface [90]. The early
barrier is attributed to substantial drug–receptor dehydration that oc-
curs far from the binding pocket. However, a comparison between the
direct and the two-step “membrane pathway” has not been studied
yet, but has triggered our interest. Therefore we have just initiated
MD calculations to compare the preference of AT1 receptor antago-
nists for one or the other pathway.
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